Cholangiocarcinoma
Not recruitingStudy Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement
Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement
- Disease:Cholangiocarcinoma
- Substances:CisplatinGemcitabine+1
Italy- Participants:18–64 years · 65+ years
- Substances:Cisplatin
- Sponsor:Incyte Corp.








